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Purpose. Examination of the potential of electroporation therapy (EPT) in a patient with metastatic soft tissue sarcoma. Patient.
A 24-year-old male who underwent extensive resection and postoperative radiotherapy for a malignant peripheral nerve sheath
tumor in the right infratemporal fossa with intracranial extension and invasion of the maxillary sinus and mandible had a re-
currence in the scar of his craniotomy for which he was initially treated with doxorubicin. After discontinuation of doxorubicin
he developed a metastatic mass at the same site for which he was treated with electroporation therapy. Method.T h es u b c u t a -
neous metastasis was inﬁltrated with bleomycin and electroporated. Results. Gradually the tumor became increasingly necrotic
and demarcated from surrounding tissue. After 10 weeks no tumor was seen anymore. The wound healed secondarily. Discussion.
Intralesional bleomycin followed by EPT is potentially eﬀective, well tolerated, and easy to perform in well accessible soft tissue
sarcoma sites.
Copyright © 2006 Remco de Bree et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Sarcomas in the head and neck area are rare. The manage-
mentofsofttissuesarcomasintheheadandneckisprimarily
surgical. However, the critical anatomy of the head and neck
limits the capacity to obtain wide surgical margins. Postop-
erative radiotherapy improves the local control rate [1, 2].
Despite this combination of treatment modalities, a higher
local recurrence rate and a worse disease-speciﬁc survival of
head and neck sarcoma patients are found as compared to
sarcomas arising at other sites [3–5]. The results of adjuvant
chemotherapy in treatment of head and neck soft tissue sar-
comas have been disappointing [6].
Electroporation therapy (EPT) is a novel local treatment
modality that uses brief, high-intensity, pulsed electrical cur-
rents to enhance the uptake of cytotoxic drugs, vaccines,
and genes into cells by producing a transient increase in cell
wall permeability [7–9]. The technique is potentially useful
in primary and secondary tumors of diﬀerent tumor types.
EPT involves the use of a specially developed delivery device,
the MedPulser (Genetronics Biomedical Corporation, San
Diego, California, USA), which consists of a circular array of
electrode needles [10]. This needle array is inserted directly
into the lesion (Figure 1). Experience has been achieved with
various tumor types, but there is yet no report on soft tissue
sarcoma.
CASE REPORT
A 24-year-old male was referred to our institute because of
hearing loss and progressive pain complaints in his face on
the right side since one month. Physicalexamination showed
aglueearontherightsideandmildtrismus.Nootherabnor-
malitieswerefound,especiallynomucosallesionsorswelling
in the neck.
CT and MRI showed a large tumor in the right infratem-
poral fossa with intracranial extension through the foramen
ovale to the cavernous sinus and growth in the posterior wall
of the maxillary sinus and destruction of the ascending part
of the mandible (Figure 2).
A transantral biopsy through the maxillary sinus showed
on histopathological examination a malignant peripheral
nerve sheath tumor. CT-scans of the chest and abdomen and
bone scintigraphy did not show signs of distant metastases.
He underwent a resection consisting of craniotomy, pa-
rotidectomy, maxillectomy, and segmental mandibula resec-
tion with selective neck dissection of level I-III. The defect
was reconstructed with a free vascularized iliac crest ﬂap. His2 Sarcoma
Figure 1: MedPulser electroporation device from Genetronics
Biomedical Corporation (San Diego, California, USA). Permission
granted by Genetronics Inc Pulse generator, foot switch, and appli-
cator.
Figure 2: MRI (coronal view) showed the tumor in the right in-
fratemporal fossa with intracranial extension and invasion of the
maxillary sinus and mandible.
postoperative course was uneventful. Histopathological ex-
amination of the surgical specimen (Figure 3)r e v e a l e dp o s i -
tive surgical margins. No lymph node metastases were found
in the neck dissection specimen. He received postoperative
radiotherapy to a total dose of 60Gy in 30 fractions.
Unfortunately, 5 months post-operative he developed a
subcutaneous metastasis in the temporal scar of the cran-
iotomy (Figure 4). An MRI showed that the underlying bone
was intact (Figure 5). Metastases were also present in the
neck on the right-hand side. He was treated with 8 cycles of
doxorubicin. There was a complete response of both lesions.
Afteronemonthhedevelopedarecurrenceonthesameplace
of his scalp again. An MRI showed no signs of recurrence in
the neck.
Since no accepted standard treatment was left, we de-
cided to propose an experimental approach in the form of
intratumoral injection of bleomycine with electroporation
therapy. After informed consent was obtained, the lesion
of 50
￿ 35mm was uniformly inﬁltrated with 60 USP-E
bleomycin(4USP-E/mL)undergeneralanesthesia.Afterﬁve
minutes the tumor and a safe margin of 0.5cm were electro-
porated using a six-needle array applicator connected to the
MedPulser system (Genetronics Inc, San Diego, California),
which transforms sinusoidal electrical energy pattern [10].
T.03.11983
Figure 3: Surgical specimen including maxillectomy, segmental
mandibula resection, and selective neck dissection.
Figure 4: Subcutaneous metastasis in the scar of the craniotomy 5
months after initial treatment.
Figure 5: MRI (axial view) showed the subcutaneous temporal
metastasis with intact underlying bone.Remco de Bree et al 3
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Figure 6: (a) Intralesional injection of bleomycin. (b) Electropora-
tion therapy.
Tumor and margin were treated with 63 overlapping appli-
cator placements (Figure 6). Gradually the tumor became
increasingly necrotic and demarcated from the surround-
ing tissue. The wound was covered by hemorrhagic crusts.
He had no pain complaints. After 10 weeks no tumor was
seen anymore. Secondary healing started from the margins
of the wound (Figure 7). Two months after EPT he devel-
oped a recurrence in his neck, for which he was treated
with ifosfamide. This wound healing was delayed due to his
chemotherapy courses. He is presently (17 months after elec-
troporation) without disease on his scalp and is doing rea-
sonably well.
DISCUSSION
Bleomycin,acytotoxicagentderivedfromactinomycetes,isa
puriﬁed glycopeptide that inhibits DNA synthesis by induc-
ingsingle-anddouble-strandedDNAbreaks.Itishydrophilic
and does not cross the cell membranes readily [11, 12]. EPT
temporarily increases the permeability of cell membranes by
creating transient pores. These pores permit direct diﬀusion
of drugs into the cells bounded by these cell membranes,
achievinghigherintracellularconcentrationsthancanbeob-
tained by intralesional injection alone. Not only does this
permit the uptake of substances into the cytoplasm, but it
alsoenhancestheuptakeinthenucleus[7].EPTdramatically
enhances the uptake of bleomycin into cells. Bleomycin has
been demonstrated in vitro to exhibit the greatest increase
(a)
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Figure 7: Lesion after 5 weeks (a), 10 weeks (b), and 12 months (c).
in cytotoxicity after EPT (a 700-fold increase) [11]. These
results have been replicated in vivo using tumor cell lines,
including melanoma, sarcoma, and carcinoma cell lines im-
planted subcutaneously in nude mice [13–15]. These models
demonstrated the superiority of bleomycin in EPT over the
other drugs tested with EPT [10, 16–18].
The electric ﬁeld for EPT is generated by the MedPulser
system. Optimization of pore formation has been achieved
using a circular six-needle array applicator. Switching po-
larity of paired needles with a second pulsing and rotating
the ﬁeld by 60 degrees for three cycles results in a circle of
positive and negative ﬁeld pulses that maximize pore forma-
tion in tumor cells within the ﬁelds. Several types of probes
with diﬀerent sizes and shapes have been developed for ap-
plication in diﬀerent kinds of tumors in diﬀerent parts of the
body [19].
In some clinical studies it has been shown that in cuta-
neous lesions the response rate of bleomycin and EPT is sig-
niﬁcantly higher than intralesional bleomycin alone, while
EPT alone showed no clinical response [16, 20]. It has been4 Sarcoma
shown that EPT with low local concentrations of bleomycin
after intravenous administration has substantially less ef-
fect than EPT following intratumoral injection of bleomycin
[18].
The majority of clinical papers on EPT report on suc-
cessfultreatmentofcutaneousmalignancies,includingsqua-
mous cell carcinomas, basal cell carcinomas, and melanomas
[18, 21, 22]. In melanoma patients complete response rates
of 72% to 89% and partial response rates of 5% to 17% have
been reported [16, 20, 22]. The clinical use of bleomycin and
EPT to treat mucosal squamous cell carcinoma of the head
and neck has been reported [23]. EPT was also used success-
fully in patients with chondrosarcoma and Kaposi’s sarcoma
[22, 24]. This is the ﬁrst clinical report on a successful treat-
ment of soft tissue sarcoma.
Although surgery with postoperative radiotherapy on
indication is likely to remain the treatment of choice for
primary resectable sarcomas, EPT after intralesional injec-
tion with bleomycin may represent an alternative to surgi-
cal resection of recurrent disease. In certain settings, like
in our patient, EPT may be advantageous in terms of lo-
cal tissue preservation, improved quality of life and costs.
Other potential advantages are outpatient treatment feasi-
bility and response in settings in which conventional ther-
apy has failed. EPT could be particularly useful in previously
operated ﬁelds, for controlling symptomatic localized dis-
ease.Thesesitesposeparticularchallengesintermsofwound
management.
Although EPT is well tolerated by patients, activation of
the MedPulser may cause unpleasant “electric shock” sensa-
tions due to spasm of underlying muscles or due to pain re-
layed by local nerves that were stimulated by the MedPulser
current.Ourpatientwastreatedundergeneralanesthesia,al-
though sedation and local anesthesia have been used in well
accessible lesions, even in an outpatient setting [20].
In conclusion, electroporation therapy is a novel treat-
ment potentially eﬀective for sarcoma utilizing intralesional
bleomycine. It is well tolerated and easy to perform in well
accessible sites.
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